Biocon Launches New Healthcare Division for Critical Illnesses & Acute Hospital Acquired Infections

Biocon today announced the launch of its new Comprehensive Care Division, dedicated to provide affordable solutions to critical illnesses like nosocomial infections, post surgical complications, trauma and medical emergencies. This would be the fifth division for Biocon, complementing the existing product portfolios in Diabetology, Oncology, Nephrology and Cardiology divisions.

?There is a perceptible increase in hospital acquired infections with respect to critical care illnesses in India. This often requires treatment with specialized anti-infectives. Biocon?s Comprehensive Care division has been set up to counter this growing challenge by providing affordable & specialized solutions to such patients.? said Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon.

With the motto of ?improving life?, Biocon?s Comprehensive Care Division will further extend the reach of Biocon?s existing branded formulations to the critical care area. The division is introducing 5 new products in the initial phase of launch for the treatment of critical illnesses like Septicemia, Nosocomial pneumonia and other acute hospital infections. These products will include platforms based on Pneumocandins (a class of Echinocandins), Lipopeptides, specialised Cephalosporins and Carbapenams.

About Biocon Limited

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013), is one of India\'s largest biotechnology companies. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon\'s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMEA acceptance. Biocon\'s robust product offering includes the world\'s first recombinant human insulin, INSUGEN and India\'s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).
For more information, visit www.biocon.com

Company :-Biocon Limited (BIOCON.NS)

User :- Paula Sengupta

Email :- paula.sengupta@biocon.com

Phone :- +91 (80) 2808 2222

Mobile:- +91 (80) 2808 2222

Url :- HTTP://www.biocon.com